What is the recommended treatment for a patient with a 6 cm primary prostate cancer and pelvic lymph node adenopathy only?

Treatment for 6 cm Primary Prostate Cancer with Pelvic Lymph Node Involvement Only

For a patient with 6 cm primary prostate cancer and pelvic lymphadenopathy (cN1M0), you should offer IMRT/VMAT plus IGRT to both the prostate and pelvis in combination with long-term ADT (at least 2 years) and 2 years of abiraterone. 1

Primary Treatment Approach

This clinical scenario represents cN1M0 disease, which falls under the locally advanced/high-risk category with nodal involvement. The 2024 EAU guidelines provide a strong recommendation specifically for this presentation 1:

• Radiation therapy: IMRT/VMAT plus IGRT targeting both the prostate and pelvic lymph nodes
• Systemic therapy: Long-term ADT (minimum 2 years) combined with 2 years of abiraterone acetate
• This combination addresses both the bulky primary tumor (6 cm) and the regional nodal disease

The guideline explicitly states to "Offer IMRT/VMAT plus IGRT to the prostate plus pelvis in combination with long-term ADT and 2 yr of abiraterone to cN1M0 patients" with a strong recommendation 1.

Rationale for This Approach

Why Radiation Over Surgery

While radical prostatectomy can be offered to selected cN1 patients as part of multimodal therapy, this carries only a weak recommendation and is specifically for cN0 disease 1. For confirmed cN1 disease with a 6 cm primary tumor:

• The bulky nature of the primary (6 cm) makes complete surgical resection more challenging
• Pelvic nodal involvement requires treatment of the entire pelvic lymphatic drainage, which radiation addresses more comprehensively
• Surgery would still require adjuvant radiation and hormonal therapy, making upfront radiation more efficient

The Role of Intensified Hormonal Therapy

The addition of abiraterone to ADT for 2 years is critical for cN1M0 patients 1. Recent evidence supports this intensified approach:

• Case reports demonstrate that dual hormonal therapy (ADT plus androgen receptor pathway inhibitors like abiraterone or enzalutamide) can effectively shrink bulky disease before or during radiation 2, 3
• This combination provides both local control and systemic disease suppression
• The 2-year duration of abiraterone specifically targets micrometastatic disease that may be present despite negative distant staging

Treatment Sequencing

1. Initiate ADT immediately with a luteinizing hormone-releasing hormone agonist/antagonist
2. Add abiraterone (with prednisone) at treatment start
3. Begin radiation therapy after 2-3 months of hormonal therapy to allow tumor shrinkage
4. Continue ADT for at least 2 years total (strong recommendation) 1
5. Continue abiraterone for 2 years total 1

Radiation Technique Specifications

For the radiation component:

• Dose to prostate: 76-78 Gy using conventional fractionation
• Pelvic nodal irradiation: Include entire pelvic lymphatic drainage
• Technique: IMRT/VMAT with IGRT to ensure accuracy and minimize toxicity
• Consider focal boost to MRI-defined dominant intraprostatic lesion (weak recommendation) 1

Alternative Consideration: Surgery-Based Approach

If surgery is strongly preferred by the patient or multidisciplinary team, the approach would be:

• Radical prostatectomy with extended pelvic lymph node dissection (ePLND) 1
• This carries only a weak recommendation for cN1 disease
• Would require adjuvant radiation to prostate bed and pelvis plus long-term ADT and abiraterone
• Higher cumulative morbidity from combined modalities
• Not the preferred first-line approach for cN1 disease

Evidence Supporting Local Treatment

The benefit of local treatment (radiation or surgery) over ADT alone for cN1 disease is supported by retrospective data showing improved overall survival (78.8% vs 49.2% at 5 years) 4. However, the guideline-recommended approach specifically for cN1M0 includes the intensified systemic therapy with abiraterone, which represents the current standard of care 1.

Common Pitfalls to Avoid

• Do not treat with ADT alone: This is inadequate for cN1 disease and misses the survival benefit of local treatment 4
• Do not omit pelvic nodal radiation: Treating only the prostate is insufficient for known nodal disease
• Do not use short-term ADT: cN1 disease requires long-term ADT (minimum 2 years) 1
• Do not omit abiraterone: The specific strong recommendation for cN1M0 includes 2 years of abiraterone 1
• Do not perform frozen section during surgery: If surgery is chosen, frozen section analysis of nodes should not determine whether to proceed 1

Monitoring and Follow-up

• Obtain baseline PSMA PET/CT if available for accurate staging and future response assessment 2, 3
• Monitor PSA response during treatment (should decline significantly)
• Assess for treatment-related toxicity, particularly genitourinary and gastrointestinal effects
• Long-term surveillance for disease progression and late toxicity